Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response Open Access (recommended)
Descriptions
- Resource type(s)
- Editorial
- Keyword
- glycogen synthase kinase-3 (GSK3)
glycogen synthase kinase-3 (GSK-3) inhibitor
COVID-19
COVID
9-ING-41
GSK-3b inhibitor
GSK-3 inhibitor
SARS-CoV21
- Rights
- Attribution 4.0 International
- Creator
-
De Souza, Andre
Tavora, Fabio A.
Mahalingam, Devalingam
Munster, Pamela N.
Safran, Howard P.
El-Deiry, Wafik S.
Carneiro, Benedito A.
- Original Bibliographic Citation
-
De Souza A, Tavora FA, Mahalingam D, Munster PN, Safran HP, El-Deiry WS, Carneiro BA. Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response. Frontiers in Immunology. 2020;11:3.
- Related URL
- Publisher
-
FRONTIERS MEDIA SA
- Date Created
-
2020-10-19
- Original Identifier
- (PMID) 33193448
- Language
- English
- Subject: MESH
-
SARS-CoV-2
Glycogen Synthase Kinase 3
Protein Kinase Inhibitors
- Subject: LCSH
-
COVID-19 (Disease)
Glycogen synthase kinase-3
Enzyme inhibitors
- DOI
-
10.3389/fimmu.2020.595289
File Details
- File Properties
-
Mime type: application/pdf
File size: 127.3 kB